JCIA
AVDL

Jackson Creek Investment Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

Jackson Creek Investment Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,640
Closed -$437K – 295
2025
Q3 		$437K Sell
28,640
-15,590
-35% -$203K 0.13% 217
2025
Q2 		$391K Buy
+44,230
New +$389K 0.11% 266

Other funds holding AVDL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.06% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jackson Creek Investment Advisors's AVDL Position: Q4 2025 in Review

Jackson Creek Investment Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 28,640 shares — an estimated $437K sold.

Jackson Creek Investment Advisors first reported a position in AVDL in Q2 2025 and held it in 2 quarters. The position peaked at $437K in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Jackson Creek Investment Advisors reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jackson Creek Investment Advisors sold 28,640 Avadel Pharmaceuticals shares in Q4 2025, an estimated $437K.
  • Jackson Creek Investment Advisors first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Jackson Creek Investment Advisors's Avadel Pharmaceuticals position peaked at $437K in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Jackson Creek Investment Advisors's 13F filing for Q4 2025, filed 9 Feb 2026.